On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), ente

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the a

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T pro

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications di

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-

Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “C

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the a

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19

BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tem

TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth

Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Cente

Adds dedicated business development leadership to support Tempest's strategic priorities Will lead C

ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th,

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the ana

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Mat

Tempest Therapeutics, Inc. (NASDAQ: TPST - Get Free Report) CEO Matthew Angel acquired 231,482 share

Tempest Therapeutics (NASDAQ: TPST - Get Free Report) is projected to announce its Q4 2025 results b

Tempest Therapeutics has entered into definitive agreements for the purchase and sale of an aggregat

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the

Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Tempest Therapeutics (NASDAQ: TPST - Ge

Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, de

Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, develo

100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile w

BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp

Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of

BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp

HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of

Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dua

Matt Angel, Ph.D.Dr. Matt Angel is an experienced biotechnology executive with expertise in leading

Tempest will issue 8,268,495 shares of its common stock, par value $0.001 per share ("Common Sto

Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "the Company"), a clinical-s